Tumour-Typing: A New Way of Assessing Cancer Treatment Options
Date of publishing: 19th Oct 2018
Tumour-Typing: A New Way of Assessing Cancer Treatment Options
Author: Pfizer Get Science Team
A method of analysing tumours could inform response to immunotherapies.
You can probably guess how your closest friend will react to a particular situation: It’s an intuition that arises out of the database of knowledge about her built up over years and stored in your mind.
Predicting how someone might react to a treatment, though, is a process that has vexed researchers working in the burgeoning field of precision medicine. How can they “know” a patient’s immune system, a patient’s cancer, and how those both change over time well enough to prescribe the best protocol?
The Immunotherapy Revolution
The biggest advancement in cancer treatment since the advent of chemotherapy is immunotherapy. The novelty of this approach is in the target: the goal of immunotherapy is to stimulate the patient’s own immune system to fight cancer by using particular components of the immune system itself, not just tumours, as a target.
One example comes from the concept of immune “checkpoints,” which are signalling mechanisms between cells that, in normal circumstances, regulate healthy immune function. Some cancers interfere with this checkpoint signalling to avoid being recognized and attacked by the immune system. With that in mind, scientists developed certain immunotherapies that disrupt those signalling malfunctions by “putting the brakes” on specific proteins such as CTLA-4, PD-1 and PD-L1, thereby freeing the immune system to fight against certain types of cancer that those proteins are involved in. These treatments have been shown to fight diseases including lung cancers, melanoma, Merkel cell carcinoma and bladder cancer.
While results can be remarkable, response rate to immunotherapy can vary widely. That’s why it’s important for researchers to better understand each patient’s immune system and identify biomarkers and molecular characteristics of a patient’s cancer that indicate whether he or she would be a good candidate to receive immunotherapy. Often, cancer patients don’t have the luxury of time to see if a therapy works, so knowing whether a treatment could be effective beforehand could save lives.
Additionally, identifying the largest group of patients who are likely to benefit from a therapy with minimal safety risks allows resources to be used more effectively.
Sizing Up Tumors
One method under exploration to determine who is most likely to benefit from immunotherapy is the use of a metric called Tumour Mutation Burden (TMB). TMB is an objective count of how many mutations a tumour has across its genome, but to understand its utility it’s important to understand what those mutations actually mean for the immune system. Paul Robbins, Senior Director in Translational Oncology at Pfizer’s La Jolla, CA site explains: “If you have acquired or are acquiring mutations, you have the potential to make unusual or inaccurate proteins that your immune system has never seen and that have the potential to be immunogenic.” In other words, the more mutations a tumour has, the higher the potential for the immune system to recognize neoantigens as a red flag that something is not right. “So generally, if a patient’s disease has already created neoantigens that can be seen by their immune system,” he adds, “there’s a higher likelihood they’ll respond to the immunotherapy.”
The issue is that immunogenicity is notoriously difficult to measure in a way that provides robust predictive value for all of the potential tumors or mutations in the world. Which is where TMB measurement could be of use. “DNA or RNA are much easier to look at with existing technologies,” explains Robbins, “meaning that TMB may be a practical surrogate biomarker for immunogenicity.”
And with TMB, he adds, you’re not just looking at a single mutation at a time—you have the potential ability to look at hundreds or thousands of markers simultaneously to get a better overall picture.
Pfizer’s translational and diagnostic teams partner with organizations that perform comprehensive genetic profiling tests to analyse those markers.
A growing body of research has shown the potential of TMB to predict, based on specific tumor types, which patients will respond to immunotherapies. One study found a significant correlation between the TMB of 27 tumor types and the objective response rate to anti–PD-1 or anti–PD-L1 therapy. The authors concluded that perhaps 55 percent of the differences in the objective response rate across cancer types could be explained by the tumor mutational burden, with some subtypes (such as Merkel- cell carcinoma, MCC) responding better than would be predicted by the TMB alone, and others (such as some colorectal cancers) responding worse. This could in part be due to differences in the origins of specific cancers—because MCC is caused by a virus, for example, the immune system could recognize those tumors more readily as they have additional, viral antigens on their surface.
However, another recent study explored the relationship between TMB and MSKCC prognostic risk classifications, a metric that describes a patient’s prognosis (favourable, intermediate, or poor) based on 5 clinical parameters. They found that in the case of metastatic renal cell carcinoma (mRCC), there was not a significant relationship between TMB and the MSKCC risk groups. In other words, the researchers couldn’t separate patients’ mutational burden into groups that also described the status of their cancer. “So in some cases,” says Robbins, “the use of TMB to determine the best course of treatment isn’t so clear. It could even be a way to exclude patients from a therapy—but we’re still exploring this space.”
And TMB is just one of many potential biomarkers that researchers are exploring. Others, such as T cell receptor clonality—which indicates, through DNA analysis, the diversity of T cells present and thus the diversity of antigens that patients’ immune systems should react to—as well as the quantity of specific T cell subtypes within a tumor, specific proteins circulating in blood, specific blood cell counts, or epigenetic markers could potentially complement the use of TMB for certain cancers. A growing body of research is looking at the utility of these markers for different types of cancer.
In the age of precision medicine, the idea of getting to know someone — and anticipating their responses — takes on a more complex and higher-stakes meaning. With tools like TMB, researchers hope to have improved powers of prediction, which in turn could give patients more hope.
https://www.getscience.com/disruptive-science/tumor-typing-new-way-assessing-cancer- treatment-options. Date Accessed: 31/August/2018
Date of Preparation: August 2018